Ann Dermatol.  2017 Aug;29(4):525-528. 10.5021/ad.2017.29.4.525.

Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review

Affiliations
  • 1Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea. snuhdm@gmail.com
  • 2Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea.

Abstract

No abstract available.


MeSH Terms

Breast Neoplasms*
Breast*
Humans
Male
Oxidoreductases*
Oxidoreductases

Figure

  • Fig. 1 Flow diagram of study selection (search date: November 24, 2015).


Reference

1. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349:2387–2398.
Article
2. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338:557–563.
Article
3. Muranushi C, Olsen CM, Green AC, Pandeya N. Can oral nonsteroidal antiinflammatory drugs play a role in the prevention of basal cell carcinoma? A systematic review and metaanalysis. J Am Acad Dermatol. 2016; 74:108–119.
Article
4. Robinson D, Garmo H, Holmberg L, Stattin P. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. Cancer Causes Control. 2015; 26:1289–1297.
Article
5. Duijnhoven RG, Straus SM, Souverein PC, de Boer A, Bosch JL, Hoes AW, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014; 25:1577–1582.
Article
6. Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013; 190:1811–1814.
Article
7. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349:215–224.
Article
8. Shenoy NK, Prabhakar SM. Finasteride and male breast cancer: Does the MHRA report show a link? J Cutan Aesthet Surg. 2010; 3:102–105.
9. Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst. 2004; 96:338–339.
Article
10. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007; 92:1659–1665.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr